Shares of Moderna Inc. MRNA,
fell 0.9% in premarket trade on Friday after the company said it is seeking approval for its COVID-19 vaccine in Japan in partnership with Takeda Pharmaceutical Co. 4502,
Takeda filed the new drug application and will be tasked with importing and distributing the vaccine from the Cambridge, Massachusetts-based company. Takeda is also conducting the Phase 1/2 study of the vaccine in adults who are at least 20 years old there; registration ended in February. If approved, Takeda will distribute 50 million doses of Moderna’s two-dose vaccine in Japan in the first half of 2021. Shares of Moderna are up 372.3% in the last 12 months, while the broader S&P 500 SPX,
is up 20.4%.